Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Upstream Bio, Inc.NASDAQ: UPB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $36.57M rose 41.7% year over year, behind the +91.5% change in trailing-twelve-month research & development. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at +94.3% a year.
Context
- Research & development amounted to 4793.5% of revenue in FY2025, up 2136.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +41.7% toward the trailing-twelve-month pace of +91.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 136.81M USD
- Year-over-year change
- +117.3%
- 3-year CAGR
- +94.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 136.81M | +117.3% |
| FY2024 | 2024-12-31 | 62.97M | +98.0% |
| FY2023 | 2023-12-31 | 31.8M | +70.4% |
| FY2022 | 2022-12-31 | 18.66M | — |
Research & Development vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +91.5% is the 2nd highest of 10, against a peer median of +7.0%.
- Research & development amounts to 4442.3% of revenue for UPB, versus a peer median of 275.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.17M USD | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $360.26M USD | +137.9% | +38.9% | — | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Jun 2026 | $270.72M USD | -4.1% | +2.0% | 2615.7% | |
| LTM Sep 2026 | $259.72M USD | +46.3% | +43.1% | 287.0% | |
| LTM Mar 2026 | $255.99M USD | +3.7% | +29.7% | 117.9% | |
| LTM Mar 2026 | $189.6M USD | +13.6% | +16.4% | 264.1% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $147.57M USD | +91.5% | +94.3% | 4442.3% |
| LTM Sep 2026 | €132.22M EUR | +7.0% | +29.5% | — | |
| LTM Sep 2026 | $100.83M USD | +9.7% | -1.1% | — | |
| Peer median (excluding UPB) | — | +7.0% | +16.4% | 275.5% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.